Timing
Purchase and sale flow
PurchasesSales
Stock, pipeline and biotech catalyst intelligence
Reported ownership activity
Activity signal
Reported purchases exceed sales by $254.8KOption exercises, awards, and grants are separated from open-market direction.Timing
Composition
Concentration
| Insider trading | Relationship | Date | Transaction | Cost | Shares | Value | Shares total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Wagner Paul A. | SEE REMARKS | Jan 01 '26 | Option Exercise | $0.00 | 1,250 | $0 | 83,342 | Jan 02 04:07 PM |
| Riley Antony A | CHIEF FINANCIAL OFFICER |
Company profile
Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's lead product candidate is the FB-102, a proprietary anti-CD122 monoclonal antibody therapeutic candidate for various autoimmune and autoimmune-related indications, such as celiac disease, vitiligo, alopecia areata, and type 1 diabetes. Forte Biosciences, Inc. is headquartered in Dallas, Texas.
Company profile supplied by Yahoo Finance. Catalyst dates can change and should be confirmed against the linked primary source.
Page updated Aug 21, 2026 · Yahoo quotes cached for one minute; reference data may be used when a live field is unavailable.
| Jan 01 '26 |
| Option Exercise |
| $0.00 |
| 375 |
| $0 |
| 41,895 |
| Jan 02 04:04 PM |
| Riley Antony A | CHIEF FINANCIAL OFFICER | Dec 30 '25 | Buy | $26.33 | 9,680 | $254,833 | 41,520 | Jan 02 04:04 PM |
Transactions may include sales, purchases, grants, and option exercises. Directional charts count only purchases and sales; follow the Form 4 link to verify the original SEC filing.